COVID-19 in a patient with granulomatosis with polyangiitis: Management tactics
E. F. Iskhakova,
E. V. Sukhorukova,
M. Yu. Badeeva,
E. V. Dyakova,
S. A. Lapshina,
T. V. Beketova,
D. I. Abdulganieva https://doi.org/10.47360/1995-4484-2023-42-46
Abstract
Patients with ANCA-associated vasculitis (AAV) cause extreme alertness during the coronavirus disease 2019 (COVID-19) pandemic, associated with many factors: the initial damage to the respiratory system (upper respiratory tract, lungs) and kidneys, immunosuppressive treatments, difficult prognosis of COVID-19 with the risk of AAV exacerbation. We present a clinical case of а moderate COVID-19 in a patient with granulomatosis with polyangiitis, who received anti-B cell therapy with rituximab (RTX) for a long time. Coronavirus pneumonia developed one year after RTX, while B-lymphocyte depletion persisted. In order to achieve an adequate antiviral immune response and prevent hyperinflammation, treatment was carried out with antiviral drugs, anticoagulants, convalescent plasma, human normal immunoglobulin, and interleukin-6 antagonist tocilizumab. Possible predictors of severe COVID-19 in patients with AAV are discussed.
About the Authors
E. F. Iskhakova
Kazan State Medical University
Russian Federation
Russian Federation
Elmira Iskhakova
420012, Russian Federation, Kazan, Butlerov str., 49
E. V. Sukhorukova
Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
420064, Russian Federation, Kazan, Orenburgskiy tract, 138
M. Yu. Badeeva
Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
420064, Russian Federation, Kazan, Orenburgskiy tract, 138
E. V. Dyakova
Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
420064, Russian Federation, Kazan, Orenburgskiy tract, 138
S. A. Lapshina
Kazan State Medical University
Russian Federation
Russian Federation
420012, Russian Federation, Kazan, Butlerov str., 49
T. V. Beketova
V.A. Nasonova Research Institute of Rheumatology;
Central Clinical Hospital of the Administrative Directorate of the President of the Russian Federation;
Moscow Polytechnic University
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
121359, Russian Federation, Moscow, Marshala Timoshenko str., 15
107023, Russian Federation, Moscow, Bolshaya Semyonovskaya str., 38
D. I. Abdulganieva
Kazan State Medical University;
Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
420012, Russian Federation, Kazan, Butlerov str., 49
420064, Russian Federation, Kazan, Orenburgskiy tract, 138
References
1. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498
2. FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2021;80:527-538. doi: 10.1136/annrheumdis-2020-218310
3. Rutherford MA, Scott J, Karabayas M, Antonelou M, Gopaluni S, Gray D, et al.; UK and Ireland Vasculitis Rare Disease Group (UKIVAS). Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: A binational, registry-based cohort study. Arthritis Rheumatol. 2021;73(9):1713-1719. doi: 10.100 2/art.41728
4. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann Rheum Dis. 2021;80:384-391. doi: 10.1136/annrheumdis-2020-218946
5. Mehta P, Porter JC, Chambers RC, Isenberg DA, Reddy V. B-cell depletion with rituximab in the COVID-19 pandemic: Where do we stand? Lancet Rheumatol. 2020;2(10):e589-e590. doi: 10.1016/S2665-9913(20)30270-8
6. Loarce-Martos J, García-Fernández A, López-Gutiérrez F, GarcíaGarcía V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol Int. 2020;40(12):2015-2021. doi: 10.1007/s00296-020-04699-x
7. Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):384-393 (In Russ.). doi: 10.47360/1995-4484-2021-384-393
8. Betrains A, Godinas L, Woei-A-Jin FJSH, Rosseels W, Van Herck Y, Lorent N, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients wwith lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192(6):1100-1105. doi: 10.1111/bjh.17266
9. Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: A report of rapid recovery. Br J Haematol. 2020;190(3):e154-e156. doi: 10.1111/bjh.16981
10. Beketova TV, Babak VV, Suprun MD. The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):37-46 (In Russ.). doi: 10.47360/1995-4484-2021-37-46
11. Quartuccio L, Treppo E, Binutti M, Del Frate G, De Vita S. Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology (Oxford). 2021:keab175. doi: 10.1093/rheumatology/keab175
12. Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al.; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/SOFRE MIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 2021;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X
13. Kant S, Morris A, Ravi S, Floyd L, Gapud E, Antichos B, et al. The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. J Nephrol. 2021;34(1):185-190. doi: 10.1007/s40620-020-00881-3
14. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722-1726. doi: 10.1016/j.ajem.2020.05.073
15. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270-2279. doi: 10.1093/eurheartj/ehaa1103
16. Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, et al. Lymphocyte subset counts in COVID-19 patients: A meta-analysis. Cytometry A. 2020;97(8):772-776. doi: 10.1002/cyto.a.24172
17. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat Med. 2020;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9
18. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in COVID-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. doi: 10.1016/j.autrev.2020.102554
19. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al.; PlasmAr Study Group. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med. 2021;384(7):619-629. doi: 10.1056/NEJMoa2031304
20. Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: Lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436-1446. doi: 10.1016/j.cmi.2020.08.005
21. Temporary guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 16 (In Russ.). URL: https://edu.rosminzdrav.ru/anonsy/anonsy/news/vremennye-metodicheskie-rekomendaciiprofilaktika-d/. (Accessed: 18th August 2022).
22. Hansrivijit P, Trongtorsak A, Gadhiya KP, Lnu K, Dimech CT, Thongprayoon C, et al. Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: A metaanalysis and metaregression. Clin Rheumatol. 2021;40(7):2843-2853. doi: 10.1007/s10067-021-05589-8
23. Hilhorst M, Winckers K, Wilde B, van Oerle R, ten Cate H, Tervaert JW. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013;40(12):2042-2046. doi: 10.3899/jrheum.130200
24. Claudel SE, Tucker BM, Kleven DT, Pirkle JL Jr, Murea M. Narrative review of hypercoagulability in small-vessel vasculitis. Kidney Int Rep. 2020;5(5):586-599. doi: 10.1016/j.ekir.2019.12.018
25. Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):5-30 (In Russ.). doi: 10.47360/1995-4484-2021-5-30
26. Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: At the crossroads of thromboinflammation and autoimmunity. Nauchno-Praktiche skaya Revmatologia = Rheumatology Science and Practice. 2020;58(4): 353-367 (In Russ.). doi: 10.47360/1995-4484-2020-353-367
27. Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.). doi: 10.47360/1995-4484-2021-239-254
Review
For citations:
Iskhakova E.F., Sukhorukova E.V., Badeeva M.Yu., Dyakova E.V., Lapshina S.A., Beketova T.V., Abdulganieva D.I. COVID-19 in a patient with granulomatosis with polyangiitis: Management tactics. Rheumatology Science and Practice. 2023;61(1):42-46. (In Russ.) https://doi.org/10.47360/1995-4484-2023-42-46
Views:
412
Email this article 